STOCK TITAN

Pliant Therapeutics Inc - PLRX STOCK NEWS

Welcome to our dedicated news page for Pliant Therapeutics (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pliant Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pliant Therapeutics's position in the market.

Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) will present four scientific posters at the 2024 American Thoracic Society International Conference. The posters focus on Bexotegrast, a novel therapeutic for fibrotic diseases. The company was also selected for a featured oral presentation on the safety and tolerability of Bexotegrast. The presentations will cover topics like biomarkers of interstitial lung disease progression and TGF-beta inhibition in the fibrotic lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
conferences
-
Rhea-AI Summary
Nimbus Therapeutics appoints Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of pharmaceutical research and development experience. Dr. Knobil's expertise will aid in accelerating Nimbus' development programs in oncology, immunology, and metabolism, aiming to bring novel therapies to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
management
-
Rhea-AI Summary
Nimbus Therapeutics appoints Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of pharmaceutical research and development experience. Dr. Knobil's expertise will aid in accelerating Nimbus' development programs in oncology, immunology, and metabolism, aiming to bring novel therapies to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
management
Rhea-AI Summary
Pliant Therapeutics, Inc. announces the implementation of BEACON-IPF, a pivotal, adaptive Phase 2b/3 trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The trial's acceptance by the EU and global health authorities will expedite late-stage development, shortening the time to Phase 3 data. Additionally, an upsized debt facility with Oxford Finance extends cash runway through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
-
Rhea-AI Summary
Pliant Therapeutics, Inc. reports positive interim data from Phase 2a INTEGRIS-PSC trial and enrollment updates for BEACON-IPF trial. Financial results show increased research and development expenses but strong cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
earnings
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) will participate in investor conferences in March, with key executives discussing the company's progress in developing therapeutics for fibrotic diseases. The conferences include TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) announced their participation in investor events, including the Oppenheimer 34th Annual Healthcare Life Sciences Conference and the Wells Fargo 2024 West Coast Biotech Tour. The company's President and CEO, Bernard Coulie, M.D., Ph.D., and Chief Medical Officer, Éric Lefebvre, M.D., will be participating in a fireside chat on February 13, 2024, at 12:00 p.m. Eastern Time. Members of Pliant's senior management will also meet with investors on February 28, 2024, as part of an invitation-only event hosted by Wells Fargo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC). The data showed that bexotegrast was well tolerated, reduced liver fibrosis markers, and improved hepatocyte function and bile flow. The 320 mg group met its primary and secondary endpoints, demonstrating antifibrotic effects. The company plans to discuss the data with regulatory authorities to discuss potential next steps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Bernard Coulie, M.D., Ph.D., President and CEO, to speak on January 9, 2024, at 7:30 a.m. Pacific Time. Webcast available on Pliant's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) announced the presentation of preclinical and clinical data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) at The Liver Meeting® 2023. The late-breaker presentation highlighted positive interim data from the trial, showing the potential of bexotegrast in treating PSC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
Pliant Therapeutics Inc

Nasdaq:PLRX

PLRX Rankings

PLRX Stock Data

876.48M
47.09M
6.63%
110.86%
11.39%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
South San Francisco

About PLRX

pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.